Utilizing native fluorescence imaging, modeling and simulation to examine pharmacokinetics and therapeutic regimen of a novel anticancer prodrug

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Wang, Jing Hung ^a   Endsley, Aaron N ^b   Green, Carol E ^c   Matin, A C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYER CORPORATION   (United States)

^c SRI INTERNATIONAL   (United States)

Author keywords

Cancer; CNOB; Fluorescence; Imaging; Modeling and simulation; Pharmacokinetics; Prodrug

Indexed keywords

6 CHLORO 9 NITRO 5 OXO 5H BENZO (A) PHENOXAZINE; 9 AMINO 6 CHLORO 5H BENZO[A]PHENOXAZINE 5 ONE; ANTINEOPLASTIC AGENT; CHRR6 PROTEIN; ONCOPROTEIN; PHENOXAZINE DERIVATIVE; UNCLASSIFIED DRUG; 6-CHLORO-9-NITRO-5-OXO-5H-BENZO(A)PHENOXAZINE; OXAZINE DERIVATIVE; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; FLUORESCENCE ANALYSIS; FLUORESCENCE IMAGING; LIQUID CHROMATOGRAPHY; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PREDICTION; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY; VOLUME OF DISTRIBUTION; ANIMAL; CANCER TRANSPLANTATION; DRUG ADMINISTRATION; HUMAN; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OPTICAL IMAGING; OXAZINES; PRODRUGS;

EID: 84979257061     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2508-6     Document Type: Article

References (26)

1. Knox RJ, Chen S. Quinone reductase-mediated nitro-reduction: clinical applications. Methods Enzymol. 2004;382:194-221.
2. Jaiswal AK. Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic Biol Med. 2000;29(3-4):254-62.
3. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst. 1996;88(5):259-69.
4. Heiss JD, Taha S, Oldfield EH, Ram Z. Intrathecal gene therapy for treatment of leptomeningeal carcinomatosis. J Neurooncol. 2011;104(1):365-9.
5. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 2000;11(17):2389-401.
6. Weedon SJ, Green NK, McNeish IA, Gilligan MG, Mautner V, Wrighton CJ, Mountain A, Young LS, Kerr DJ, Searle PF. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int J Cancer. 2000;86(6):848-54.
7. Yazawa K, Fisher WE, Brunicardi FC. Current progress in suicide gene therapy for cancer. World J Surg. 2002;26(7):783-9.
8. Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG, Collins SI, Searle PF, Hull D, Peers E, et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol Ther. 2009;17(7):1292-9.
9. Terekhov M, Scholz A, Schreiber LM. Measurement of anesthetic uptake kinetics in the brain using (19)F MRI and cross-correlation analysis after pulsed application. MAGMA. 2014;27(1):107-11.
10. Barak Y, Thorne SH, Ackerley DF, Lynch SV, Contag CH, Matin A. New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution. Mol Cancer Ther. 2006;5(1):97-103.
11. Thorne SH, Barak Y, Liang W, Bachmann MH, Rao J, Contag CH, Matin A. CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy. Mol Cancer Ther. 2009;8(2):333-41.
12. Barak Y, Nov Y, Ackerley DF, Matin A. Enzyme improvement in the absence of structural knowledge: a novel statistical approach. ISME J. 2008;2(2):171-9.
13. Eswaramoorthy S, Poulain S, Hienerwadel R, Bremond N, Sylvester MD, Zhang YB, Berthomieu C, Van Der Lelie D, Matin A. Crystal structure of ChrR--a quinone reductase with the capacity to reduce chromate. PLoS One. 2012;7(4):e36017.
14. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999;17(2):163-70.
15. Barak Y, Schreiber F, Thorne SH, Contag CH, Debeer D, Matin A. Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing. BMC Cancer. 2010;10:146.
16. Laginha KM, Verwoert S, Charrois GJR, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005;11(19):6944-9.
17. Lankelma J, Dekker H, Luque RF, Luykx S, Hoekman K, van der Valk P, van Diest PJ, Pinedo HM. Doxorubicin gradients in human breast cancer. Clin Cancer Res. 1999;5(7):1703-7.
18. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther. 2008;324(1):95-102.
19. Yan ZQ, Zhan CY, Wen ZY, Feng LL, Wang F, Liu Y, Yang XK, Dong Q, Liu M, Lu WY. LyP-1-conjugated doxorubicin-loaded liposomes suppress lymphatic metastasis by inhibiting lymph node metastases and destroying tumor lymphatics. Nanotechnology. 2011;22(41):415103.
20. Zheng JH, Chen CT, Au JLS, Wientjes MG. Time- and concentration-dependent penetration of doxorubicin in prostate tumors. Aaps Pharmsci. 2001;3(2):E15.
21. Food and Drug Administration. Guidance for industry, bioavailability and bioequivalence studies for orally administered drug products: general considerations. In. Edited by CDER, Revision 1 edn; 2003: 26.
22. Kanada M, Bachmann MH, Hardy JW, Frimannson DO, Bronsart L, Wang A, Sylvester MD, Schmidt TL, Kaspar RL, Butte MJ, et al. Differential fates of biomolecules delivered to target cells via extracellular vesicles. Proc Natl Acad Sci U S A. 2015;112(12):E1433-42.
23. Zou S, Scarfo K, Nantz MH, Hecker JG. Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells. Int J Pharm. 2010;389(1-2):232-243.
24. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem. 1995;270(32):18997-9007.
25. Okumura K, Nakase M, Inui M, Nakamura S, Watanabe Y, Tagawa T. Bax mRNA therapy using cationic liposomes for human malignant melanoma. J Gene Med. 2008;10(8):910-7.
26. Kormann MS, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber-Jonat S, Huppmann M, Mays LE, Illenyi M, Schams A, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol. 2011;29(2):154-7.